TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01908127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tell- show- do
Description: Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: film modelling
Description: the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of local anesthesia solution
Description: A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of local anesthesia solution
Description: A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal cavity preparation
Description: the occlusal cavity was prepared for pulpotomy and restoration of the teeth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: occlusal cavity preparation
Description: the occlusal cavity was prepared for pulpotomy and restoration of the teeth
Study: NCT01545635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate
Description: Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10\<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT \>90sec and FIBTEM A10\>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma blood type 0, A, B and AB
Description: Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
Study: NCT03258359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PACTN
Description: To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.
Study: NCT04165681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limbix Spark
Description: 5-week, self-guided mobile + VR CBT-based program for adolescent depression
Study: NCT01127581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 200
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone Vaginal Insert (DVI)
Description: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT01439893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhNRG-1
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study: NCT06293261

Intervention type: DRUG
Intervention: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
Description: Experimental only, not included active and placebo comparator

Intervention type: DRUG
Intervention: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
Description: Experimental only, not included active and placebo comparator

Intervention type: DRUG
Intervention: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
Description: Experimental only, not included active and placebo comparator

Intervention type: DRUG
Intervention: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
Description: Experimental only, not included active and placebo comparator
Study: NCT01439893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study: NCT00314171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
Description: One drop in the study eye(s) twice daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)
Description: One drop in the study eye(s) twice daily for 12 months
Study: NCT02236130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional block
Description: Single shot peripheral nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General Anesthesia with O2/N2O/Sevoflurane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: General Anesthesia with O2/N2O/Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetic Ropivacaine
Description: 0.5% Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids Morphine
Description: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids Morphine
Description: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral pain medication Acetaminophen with Hydrocodone
Description: Acetaminophen with Hydrocodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral pain medication Acetaminophen with Hydrocodone
Description: Acetaminophen with Hydrocodone
Study: NCT02353130

Intervention type: DRUG
Intervention: Memantine-XR
Description: Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
Study: NCT00675649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 148 / Golimumab
Description: 100 mg sc injection every 4 weeks from week 0 to week 20

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo sc injection every 4 weeks from week 0 to week 20
Study: NCT04493450

Intervention type: OTHER
Intervention: Documentation of cancer treatment side effects
Description: Standardized documentation of occurred side effects
Study: NCT03312062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling Exercise
Description: Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
Study: NCT01434342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Patch
Description: Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, \& 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
Study: NCT01572649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study: NCT01107002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer group
Description: Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
Study: NCT00617448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diathermy haemorrhoidectomy under espinal anesthesia
Description: For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diathermy haemorrhoidectomy under local anesthesia
Description: For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure haemorrhoidetomy under spinal anestesia
Description: For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
Study: NCT05929742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early rehabilitation
Description: Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
Study: NCT03559543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocoxin-Viusid
Description: An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study.
Study: NCT00968955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local infiltration with ropivacaine 0,2% (150 ML)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Local infiltration with ropivacaine 0,2% (150 ML)
Study: NCT03341845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: axitinib in combination with avelumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: axitinib in combination with avelumab
Study: NCT04165356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mouth-rinse with 0.12% clorhexidine
Description: mouthwash with 0.12% chlorhexidine twice daily compared to isotonic bicarbonated solution twice daily for the prevention of any infection associated with mechanical ventilation in patients requiring endotracheal intubation in the intensive care unit of a third level hospital.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate
Description: mouthwash with sotonic solution with 1.5% sodium bicarbonate twice daily for the prevention of any intection associated with mechanical ventilation
Study: NCT04644120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-47D11
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-2B04
Description: Intervenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-2B04
Description: Intervenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-2B04
Description: Intervenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-2B04
Description: Intervenous (IV) Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-2B04
Description: Intervenous (IV) Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-2B04
Description: Intervenous (IV) Infusion
Study: NCT04591756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Fit Testing
Description: Qualitative fit testing with denatonium benzoate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Fit Testing
Description: Qualitative fit testing with denatonium benzoate
Study: NCT06392152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Focal Mass Drug Administration with Primaquine
Description: A population census was conducted in each village in August 2019 to record the demographic information and malaria histories of the villagers. Vulnerable groups such as pregnant women, breastfeeding mothers, and children under 7 years were excluded from PQ administration.~Both Group 1 \&2 underwent a preliminary clinical assessment to exclude individuals with G6PD deficiency and low hemoglobin levels.~Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.~As per cross-over design, eligible individulas from Group-1 received PQ-MDA in year 1 and Group-2 received PR-MDA in the following year.
Study: NCT01146535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Description: 150 IU lozenges bid for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg capsules bid for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: 75 mg capsules bid for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maltose
Description: 200 mg maltose lozenges bid for 5 days
Study: NCT01992250

Intervention type: DEVICE
Group type: OTHER
Intervention: Visica 2 Treatment System
Description: Cryoablation

Intervention type: DEVICE
Group type: OTHER
Intervention: Visica 2 Treatment System
Description: Cryoablation
Study: NCT01673984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl® SR 22.5mg
Description: 22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
Description: For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
Study: NCT06024811

Intervention type: BEHAVIORAL
Intervention: supporting nursing care
Description: Supportive nursing care was applied during the intrapartum period. Latent Active Transition phase,birt, postpartum period
Study: NCT00943592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Doses ranging from 100 to 140 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 20mg/d x5

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of donor, bone marrow and auto.
Study: NCT00878800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXD101
Description: Administered in combination with doxorubicin (BelDox)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered in combination with PXD101 (BelDox)
Study: NCT03564769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: Individuals randomized to the intervention group will receive skin cancer screening educational materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAD SPOTmeⓇ skin cancer screening
Description: All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAD SPOTmeⓇ skin cancer screening
Description: All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.
Study: NCT00500734

Intervention type: PROCEDURE
Intervention: Blood Sample
Description: One time blood draw of 2 teaspoons.
Study: NCT01608464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan and docetaxel
Description: combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, fluorouracil and concurrent radiation therapy
Description: Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
Study: NCT02051790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
Study: NCT02407873

Intervention type: OTHER
Intervention: Non
Study: NCT03844425

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional VFR
Description: Conventional retainers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFR from SLA
Description: SLA has better finishing compared to FDM but it is more expensive.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFR from FDM
Description: FDM has poorer finishing compared to SLA but it is cheaper.
Study: NCT03761485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of Dentifrice Fluoride
Description: Use of few of dentifrice on brushing during a year

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of Dentifrice Fluoride
Description: Use of few of dentifrice on brushing during a year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Dentifrice Fluoride
Description: Use of few of dentifrice on brushing during a year
Study: NCT04658979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary tele-rehabilitation
Description: All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
Study: NCT02225808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for anxiety in autism
Study: NCT02946892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be given for 12 weeks and then an exercise test will be performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given for 12 weeks and then an exercise test will be performed